The antipsychotic risperidone is associated with increased stoke risk in older adults with dementia, even in those without cardiovascular disease (CVD), results of a large population-based study ...
The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment for bipolar I disorder, drugmakers Teva Pharmaceuticals and Medincell said. A web-based guided self-help ...
Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a ...
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed ...
NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval ...
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal” or the "Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback